Bukwang Pharmaceutical Co., Ltd. (KRX:003000)
South Korea flag South Korea · Delayed Price · Currency is KRW
4,005.00
+70.00 (1.78%)
Sep 18, 2026, 3:30 PM KST

Bukwang Pharmaceutical Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
215,093200,714160,087125,928190,909182,491
Other Revenue
----0-0-
215,093200,714160,087125,928190,909182,491
Revenue Growth
20.05%25.38%27.13%-34.04%4.61%7.56%
Cost of Revenue
119,808109,18686,02379,012111,763106,942
Gross Profit
95,28591,52874,06446,91679,14775,550
Selling, General & Admin
57,71755,64545,96651,27449,79743,477
Research & Development
22,18819,40123,43134,55124,27422,465
Amortization of Goodwill & Intangibles
742.97558.7114.7731.8633.4931.76
Other Operating Expenses
1,561470.862,2252,0781,3451,317
Operating Expenses
83,63477,36472,44784,41379,37769,928
Operating Income
11,65114,1641,618-37,497-230.645,622
Interest Expense
-3,895-3,895-6,490-3,808-1,760-1,408
Interest & Investment Income
4,7114,7114,4193,0801,440268.16
Earnings From Equity Investments
-4.0618.33343.13-1,50158.57-1,361
Currency Exchange Gain (Loss)
-444.43-444.43-64.59-177.4488.47322.31
Other Non Operating Income (Expenses)
4,691409.71-1,755867.73-113.7333.63
EBT Excluding Unusual Items
16,70914,963-1,930-39,036-517.653,477
Impairment of Goodwill
-418.17-418.17-915.64---
Gain (Loss) on Sale of Investments
-6,009-6,009738.9-564.4-567.4790.53
Gain (Loss) on Sale of Assets
374.4374.453.7530.6452.25220.05
Asset Writedown
-2,524-2,524-8,670---
Other Unusual Items
--7,753---
Pretax Income
8,1326,386-2,970-39,569-1,0333,787
Income Tax Expense
-568.54-6,047489.25-5,1633,2166,584
Earnings From Continuing Operations
8,70112,433-3,459-34,407-4,249-2,797
Minority Interest in Earnings
77.6124.48817.443,0771,7741,880
Net Income
8,77812,558-2,641-31,330-2,475-916.62
Net Income to Common
8,77812,558-2,641-31,330-2,475-916.62
Net Income Growth
5.00%-----
Shares Outstanding (Basic)
988368686868
Shares Outstanding (Diluted)
988368686868
Shares Change
37.68%20.67%---0.01%-0.25%
EPS (Basic)
89.80152.01-38.59-457.67-36.15-13.39
EPS (Diluted)
89.79152.00-39.00-458.00-36.15-13.39
EPS Growth
-23.48%-----

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-1,53614,20632,424-12,19612,16325,740
Free Cash Flow Per Share
-15.71171.97473.65-178.17177.69375.98
Dividend Per Share
125.000125.000----
Dividend Growth
------
Gross Margin
44.30%45.60%46.27%37.26%41.46%41.40%
Operating Margin
5.42%7.06%1.01%-29.78%-0.12%3.08%
Profit Margin
4.08%6.26%-1.65%-24.88%-1.30%-0.50%
Free Cash Flow Margin
-0.71%7.08%20.25%-9.69%6.37%14.11%
EBITDA
16,76019,6525,724-33,2044,88610,465
EBITDA Margin
7.79%9.79%3.57%-26.37%2.56%5.73%
D&A For EBITDA
5,1085,4894,1064,2925,1174,843
EBIT
11,65114,1641,618-37,497-230.645,622
EBIT Margin
5.42%7.06%1.01%-29.78%-0.12%3.08%
Effective Tax Rate
-----173.85%
Advertising Expenses
-9,0186,30712,76412,1816,622